newsfilter
← Latest News
GlobeNewswire·

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society